A fundamental change emerging in locally advanced rectal cancer management: a case report-Reference-Cited by-同舟云学术

A fundamental change emerging in locally advanced rectal cancer management: a case report

Published:2022-09-01 Issue:9 Volume:2022 Page:
ISSN:2042-8812
Container-title:Journal of Surgical Case Reports
language:en
Short-container-title:

Author:

Edwards-Murphy Amy¹²^ORCID,Earley Helen¹,Creavin Ben¹,McCullough Peter¹,Cooke Fiachra¹,Neary Peter¹²

Affiliation:

1. Department of Academic Surgery, University Hospital Waterford , Dunmore Road, Waterford , Ireland

2. Department of Academic Surgery, University College Cork , Cork , Ireland

Abstract

Abstract Treatment of locally advanced rectal cancer remains a challenge in colorectal surgery. It has had an evolving landscape over the past three decades. Implementation of total neoadjuvant therapy (TNT) as a novel approach to management has begun globally but long-term outcomes and data analysis to identify optimal schedules are eagerly awaited. We report a case of locally advanced rectal cancer management in a young male with a complete pathological response to TNT.

Publisher

Oxford University Press (OUP)

Subject

Surgery

Link

https://academic.oup.com/jscr/article-pdf/2022/9/rjac405/45922800/rjac405.pdf

Reference8 articles.

1. Total neoadjuvant therapy for locally advanced rectal cancer: the fuse is lit;Healey Bird;J Br Surg,2020

2. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

3. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

4. Early-onset colorectal cancer: initial clues and current views;Hofseth;Nat Rev Gastroenterol Hepatol,2020

5. Non-Operative Management of Patients with Rectal Cancer: Lessons Learnt from the OPRA Trial